Description

Edotreotide is a somatostatin analogue. Edotreotide bound to various radionuclides, has the potential for the research and diagnosis of certain types of cancer[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Cancer-programmed cell death–C65H92N14O18S2—-[1]Norenberg JP, et al. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin Cancer Res. 2006;12(3 Pt 1):897-903.–204318-14-9–1421.64–98.15–O=C([C@@H](NC([C@@](CSSC[C@@H](C(N[C@H](CO)[C@H](O)C)=O)NC([C@@]([C@H](O)C)([H])NC([C@@](CCCCN)([H])NC1=O)=O)=O)([H])NC([C@H](NC(CN2CCN(CCN(CC(O)=O)CCN(CC(O)=O)CC2)CC(O)=O)=O)CC3=CC=CC=C3)=O)=O)CC4=CC=C(O)C=C4)N[C@@H]1CC5=CNC6=C5C=CC=C6–Cancer–DMSO : 100 mg/mL (ultrasonic)|H2O : 5 mg/mL (ultrasonic;warming;heat to 60°C)–Others—-Others–Peptides